Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec:113 Suppl 1:S82-S87.
doi: 10.1016/j.ijid.2021.02.090. Epub 2021 Mar 10.

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2

Affiliations

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2

Linda Petrone et al. Int J Infect Dis. 2021 Dec.

Abstract

Objectives: The interaction of COVID-19 and tuberculosis (TB) are still poor characterized. Here we evaluated the immune response specific for Micobacterium tuberculosis (Mtb) and SARS-CoV-2 using a whole-blood-based assay-platform in COVID-19 patients either with TB or latent TB infection (LTBI).

Methods: We evaluated IFN-γ level in plasma from whole-blood stimulated with Mtb antigens in the Quantiferon-Plus format or with peptides derived from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S).

Results: We consecutively enrolled 63 COVID-19, 10 TB-COVID-19 and 11 LTBI-COVID-19 patients. IFN-γ response to Mtb-antigens was significantly associated to TB status and therefore it was higher in TB-COVID-19 and LTBI-COVID-19 patients compared to COVID-19 patients (p ≤ 0.0007). Positive responses against CD4-S were found in 35/63 COVID-19 patients, 7/11 LTBI-COVID-19 and only 2/10 TB-COVID-19 patients. Interestingly, the responders in the TB-COVID-19 group were less compared to COVID-19 and LTBI-COVID-19 groups (p = 0.037 and 0.044, respectively). Moreover, TB-COVID-19 patients showed the lowest quantitative IFN-γ response to CD4-S compared to COVID-19-patients (p = 0.0336) and LTBI-COVID-19 patients (p = 0.0178).

Conclusions: Our data demonstrate that COVID-19 patients either TB or LTBI have a low ability to build an immune response to SARS-CoV-2 while retaining the ability to respond to Mtb-specific antigens.

Keywords: COVID-19; Co-infection; IFN-gamma response; M. tuberculosis; Tuberculosis; Whole blood assay.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tuberculosis comorbidity impairs the SARS-CoV-2-specific immune response. Evaluation of the IFN-γ response to TB1 (A), TB2 (B), CD4S (C) and mitogen in COVID-19, TB-COVID-19, LTBI-COVID-19 and NO COVID-19 subjects. A. The IFN-γ level in COVID-19-patients was significantly lower compared to TB-COVID-19 and LTBI-COVID-19-patients in response to TB1. B. The IFN-γ level in COVID-19-patients was significantly lower compared to TB-COVID-19 and LTBI-COVID-19-patients in response to TB2. C. TB-COVID-19-patients showed the lowest IFN-γ levels in response to CD4-S compared to “COVID-19” patients and to LTBI-COVID-19-patients. D. No significant differences were found in response to the mitogen among the groups evaluated. Footnotes: Horizontal bars represent medians. IFN-γ was measured by ELISA in harvested stimulated plasma. Responses were compared using the Mann–Whitney test with Bonferroni correction; differences were considered significant at p-values of ≤0.05 or 0.016. Red dots indicate patients scored indeterminate to QFT-Plus. Blue p values indicate differences almost significant. COVID-19: CoronaVIrus Disease-2019; TB: tuberculosis; LTBI: latent TB infection; CD: cluster differentiation; MIT: mitogen.

References

    1. Boulle A., Davies M.A., Hussey H., Ismail M., Morden E., Vundle Z., et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1198. - DOI - PMC - PubMed
    1. Cantini F., Goletti D., Petrone L., Najafi Fard S., Niccoli L., Foti R. Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review. Drugs. 2020 doi: 10.1007/s40265-020-01421-w. - DOI - PMC - PubMed
    1. Cantini F., Nannini C., Niccoli L., Petrone L., Ippolito G., Goletti D. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm. 2017;2017:8909834. doi: 10.1155/2017/8909834. - DOI - PMC - PubMed
    1. Durrheim D.N., Crowcroft N.S., Strebel P.M. Measles — the epidemiology of elimination. Vaccine. 2014;32:6880–6883. S0264-410X(14)01451-0. - PubMed
    1. Falasca L., Nardacci R., Colombo D., Lalle E., Di Caro A., Nicastri E., et al. Postmortem findings in Italian patients with COVID-19: a descriptive full autopsy study of cases with and without comorbidities. J Infect Dis. 2020;222:1807–1815. doi: 10.1093/infdis/jiaa578. - DOI - PMC - PubMed